700 Technology Square, 3rd Floor
Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan takes advantage of recent scientific breakthroughs in rare diseases and leveraging a creative approach to drug development and operates in an externally focused, highly collaborative and capital efficient manner.
The accelerator is targeting programs that can make a significant impact on the lives of patients with rare diseases, focusing on advancements with large clinical benefit.
Cydan focuses on identifying promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data are generated during a rigorous diligence and de-risking process to enable subsequent financing and formation of successful stand-alone companies and strategic partnerships.
Based in Cambridge, Mass., Cydan was founded by a management team with extensive drug development, business development and commercialization experience across the biopharmaceutical, venture capital and consulting industries, and strong relationships with non-profit organizations and research foundations.
Cydan launched in 2013 with $26 million in financing led by New Enterprise Associates (NEA), Pfizer Venture Investments, Lundbeckfond Ventures and Bay City Capital with participation from Alexandria Real Estate Equities, Inc.